Medical Devices - Insulin Delivery Systems / Automated Insulin Delivery (AID)
Strategic Profile
The Omnipod 5 Automated Insulin Delivery System integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections and can be controlled by a compatible personal smartphone in the U.S. By early 2026, the company has successfully debunked the GLP-1 death sentence narrative and proved that its tubeless, pharmacy-distributed model is the most scalable way to manage insulin-dependent diabetes. Adjusted Diluted Earnings Per Share are anticipated to grow at a CAGR of 25%+.
Cyborg Score Rationale
Insulet offers a rare combination of 20%+ revenue growth, expanding margins, and a dominant market position in a sector with high barriers to entry. According to 19 analysts, the average rating for PODD stock is Strong Buy with a 12-month price target of $366.26, an increase of 51.48% from the latest price. The company has strong positioning in an underpenetrated market with robust innovation pipeline.
Top Insights
The expected 2026 launch of a Pod specifically for Type 2 basal users could double the company's daily new patient starts
Insulet unveiled enhancements to Omnipod 5 intended to launch in 2026, along with two next-generation systems expected to drive the next phase of the company's growth
International rollout expansion into markets like France and Japan is still in early stages, offering significant greenfield growth
In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year
Named Competitors
Paradigm — Tubed insulin pump system
t:slim — Tubed automated insulin delivery system
Multiple Daily Injections — Traditional insulin delivery method
Recent Developments
(February 2026) 2025 financial results announcement scheduled for February 18, 2026
(January 2026) Insulet debuted at CES 2026 showcasing liveable technology vision for connected health
(January 2026) FDA 510(k) clearance for significant enhancements to Omnipod 5 Automated Insulin Delivery System
(November 2025) 2025 Investor Day outlined strategic plan and innovation roadmap for 2025-2028
Open the full interactive Insulet Corporation report
30-page strategic research, 15-min analyst-debate audio briefing, full Cyborg Score breakdown across 11 dimensions.